Crizotinib and lorlatinib (Figure 1) are second‐ and third‐ generation therapeutic inhibitors targeting anaplastic lymphoma kinase (ALK) and are commonly used drugs for the treatment of lung cancer. This evidence concerns the gene ALK and lung carcinoma.